Author Interviews, Macular Degeneration, Ophthalmology, PNAS / 27.10.2021 Interview with: Bradley D. Gelfand PhD Center for Advanced Vision Science Department of Ophthalmology Department of Biomedical Engineering University of Virginia School of Medicine Charlottesville, VA 22908 What is the background for this study? Would you briefly describe dry AMD? Response: Dry age-related macular degeneration (AMD) is a form of AMD that affects about 11 million people in the United States, and many millions more worldwide. Dry AMD is a disease affecting the macula, the central part of our retina that is responsible for fine visual acuity tasks - things like reading, driving, and recognizing faces. Dry AMD typically develops in people in their 6th, 7th, and 8th decades of life and begins with small changes to the retina that are unlikely to affect vision at first. As the disease progresses, it can develop into more advanced stages ("wet" AMD and geographic atrophy), which can cause blindness. Unfortunately, there is no approved treatment that can prevent dry AMD or its progression to advanced blinding stages. (more…)
AHA Journals, Author Interviews, Diabetes, Stroke / 08.02.2019 Interview with: Karen C. Johnston MD Professor and Chair, Neurology School of Medicine University of Virginia What is the background for this study? Response: We know that acute ischemic stroke patient with hyperglycemia at presentation have worse outcomes. We also know if we lower the glucose too low that this is bad for ischemic brain also. T he SHINE trial addressed a world wide debate about whether intensive treatment of hyperglycemia is beneficial. We assessed the efficacy and safety of an intensive glucose control protocol with a target glucose of 80-130 mg/dL compared to a more standard protocol with a target of less than 180 mg/dL. (more…)